Originally published on AI Tech Connect.
At a glance $2.1 billion Series B closed on 12 May 2026 — one of the largest applied-AI rounds of the year. Thrive Capital leads the round, joining a syndicate that includes Alphabet, GV, MGX, Temasek, CapitalG and the UK Sovereign AI Fund. Use of proceeds: scale the IsoDDE drug-design engine, advance internal therapeutic candidates toward the clinic, expand partnered programmes, and hire across AI, engineering, drug design and clinical disciplines. Three sites — London (HQ), Cambridge Massachusetts and Lausanne — anchoring a transatlantic applied-AI biotech footprint. Builder takeaway: vertical AI for regulated sectors is no longer a side bet. The capital is flowing toward applied frontier-AI in pharma, biology and defence. Pro tip If you are an AI engineer thinking about your next move,…
